dr. kris on predicting benefit with osimertinib in egfr nsclc
Published 5 years ago • 276 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
2:20
dr. kris on the relay trial in egfr nsclc
-
1:28
dr. kris on the future of immunotherapy and targeted therapy in lung cancer
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
1:36
dr. mark kris discusses dacomitinib for patient with egfr-positive lung cancer
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
1:04
dr. kris discusses egfr mutation testing
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
1:22
dr. kris on combination chemotherapy approaches in nsclc
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
1:17
dr. kris on personalizing therapy in lung cancer
-
2:23
dr. zhu on primary resistance to osimertinib in egfr-mutant nsclc
-
1:06
dr. shum on patient consultation of osimertinib in nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
1:37
dr. levy on the dfs benefit achieved with adjuvant osimertinib in egfr nsclc